Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Recombinant human thrombopoietin attenuates carboplatin-induced severe thrombocytopenia and the need for platelet transfusions in patients with gynecologic cancer
Autore:
Vadhan-Raj, S; Verschraegen, CF; Bueso-Ramos, C; Broxmeyer, HE; Kudelka, AP; Freedman, RS; Edwards, CL; Gershenson, D; Jones, D; Ashby, M; Kavanagh, JJ;
Indirizzi:
Univ Texas, MD Anderson Canc Ctr, Dept Bioimmunotherapy, Houston, TX 77030USA Univ Texas Houston TX USA 77030 pt Bioimmunotherapy, Houston, TX 77030USA Indiana Univ, Sch Med, Indianapolis, IN USA Indiana Univ Indianapolis IN USA ana Univ, Sch Med, Indianapolis, IN USA Genentech Inc, Ctr Oncol, Med Affairs, S San Francisco, CA 94080 USA Genentech Inc S San Francisco CA USA 94080 S San Francisco, CA 94080 USA
Titolo Testata:
ANNALS OF INTERNAL MEDICINE
fascicolo: 5, volume: 132, anno: 2000,
pagine: 364 - 368
SICI:
0003-4819(20000307)132:5<364:RHTACS>2.0.ZU;2-D
Fonte:
ISI
Lingua:
ENG
Soggetto:
COLONY-STIMULATING FACTOR; HUMAN MEGAKARYOCYTE GROWTH; PHASE-I TRIAL; C-MPL LIGAND; OVARIAN-CANCER; LUNG-CANCER; CHEMOTHERAPY; ESCALATION; CLONING;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
20
Recensione:
Indirizzi per estratti:
Indirizzo: Vadhan-Raj, S Univ Texas, MD Anderson Canc Ctr, Dept Bioimmunotherapy, Box002,1515 Holcombe Blvd, Houston, TX 77030 USA Univ Texas Box 002,1515 Holcombe Blvd Houston TX USA 77030 A
Citazione:
S. Vadhan-Raj et al., "Recombinant human thrombopoietin attenuates carboplatin-induced severe thrombocytopenia and the need for platelet transfusions in patients with gynecologic cancer", ANN INT MED, 132(5), 2000, pp. 364-368

Abstract

Background: Thrombocytopenia is a significant problem in the treatment of cancer. Objective: To assess the clinical safety of therapy with recombinant humanthrombopoietin (rhTPO) and its ability to ameliorate chemotherapy-induced severe thrombocytopenia. Patients: 29 patients with gynecologic cancer. Intervention: Recombinant human thrombopoietin was given before chemotherapy and after a second cycle of carboplatin therapy. Measurements: Peripheral blood counts and platelet transfusions. Design: Phase I/II clinical cohort studySetting: The University of Texas M.D. Anderson Cancer Center, Houston, Texas. Results: Administration of rhTPO after chemotherapy significantly reduced the degree and duration of thrombocytopenia and enhanced platelet recovery. In patients who received the optimal biological dose of rhTPO (1.2 mu g/kgof body weight) in cycle 2 (carboplatin plus rhTPO), the mean platelet count nadir was higher (44 x 10(9) cells/L and 20 x 10(9) cells/L; P = 0.002) and the duration of thrombocytopenia was shorter (days with a platelet count <20 x 10(9) cells/L 1 and 4 [P = 0.002]; days with a platelet count <50 x10(9) cells/L 4 and 7 [P = 0.006]) than in cycle 1 (carboplatin only). Theneed for platelet transfusion in this group was reduced from 75% of patients in cycle 1 to 25% of patients in cycle 2 (P = 0.013). Conclusions: Therapy with rhTPO seems to be safe and may attenuate chemotherapy-induced severe thrombocytopenia and reduce the need for platelet transfusions.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 09/04/20 alle ore 13:25:47